• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Hormone resistance in cancer.

作者信息

Phoenix John T, Budreika Audris, Kostlan Raymond J, Hwang Justin H, Fanning Sean W, Kregel Steven

机构信息

Department of Cancer Biology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, United States.

Integrated Program in Biomedical Science, Biochemistry, Molecular and Cancer Biology, Loyola University Chicago, Maywood, IL, United States.

出版信息

Front Endocrinol (Lausanne). 2023 Aug 24;14:1272932. doi: 10.3389/fendo.2023.1272932. eCollection 2023.

DOI:10.3389/fendo.2023.1272932
PMID:37693345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10484586/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c563/10484586/f762ca2711a4/fendo-14-1272932-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c563/10484586/f762ca2711a4/fendo-14-1272932-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c563/10484586/f762ca2711a4/fendo-14-1272932-g001.jpg

相似文献

1
Editorial: Hormone resistance in cancer.社论：癌症中的激素抵抗
Front Endocrinol (Lausanne). 2023 Aug 24;14:1272932. doi: 10.3389/fendo.2023.1272932. eCollection 2023.
2
Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).通过线粒体丙酮酸载体 (MPC) 将激素敏感型前列腺癌重编程为致死性神经内分泌癌谱系。
Mol Metab. 2022 May;59:101466. doi: 10.1016/j.molmet.2022.101466. Epub 2022 Feb 25.
3
The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.表观遗传变化在治疗诱导的神经内分泌前列腺癌谱系可塑性中的作用。
Front Endocrinol (Lausanne). 2022 Jul 14;13:926585. doi: 10.3389/fendo.2022.926585. eCollection 2022.
4
Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.前列腺癌中的谱系可塑性和治疗耐药性：遗传学、表观遗传学和进化的交集。
Front Endocrinol (Lausanne). 2023 Jun 30;14:1191311. doi: 10.3389/fendo.2023.1191311. eCollection 2023.
5
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.FOXA2 驱动神经内分泌前列腺癌中的谱系可塑性和 KIT 通路激活。
Cancer Cell. 2022 Nov 14;40(11):1306-1323.e8. doi: 10.1016/j.ccell.2022.10.011. Epub 2022 Nov 3.
6
Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.促性腺激素释放激素及促性腺激素释放激素类似物的临床应用
Fertil Steril. 1983 Mar;39(3):257-66.
7
Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.无翅型MMTV整合位点家族成员5（Wntless）的表达促进谱系可塑性，并与神经内分泌前列腺癌相关。
Am J Clin Exp Urol. 2022 Oct 15;10(5):299-310. eCollection 2022.
8
Neuropeptides and hormones in hypothalamus-pituitary axis of Chinese sturgeon (Acipenser sinensis).中国鲟（Acipenser sinensis）下丘脑-垂体轴中的神经肽和激素。
Gen Comp Endocrinol. 2023 Jan 1;330:114135. doi: 10.1016/j.ygcen.2022.114135. Epub 2022 Sep 28.
9
Nuclear hormone receptor variants: their role in malignancy and progression to hormone resistance in cancer.核激素受体变体：它们在恶性肿瘤及癌症激素抵抗进展中的作用。
Acta Endocrinol (Copenh). 1991;125 Suppl 1:48-53.
10
Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.类固醇激素受体作为乳腺癌和前列腺癌治疗的靶点——最新进展、耐药机制及新方法
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):191-200. doi: 10.1016/j.jsbmb.2004.12.002. Epub 2005 Jan 28.

引用本文的文献

1
Nuclear receptors in metabolic, inflammatory, and oncologic diseases: mechanisms, therapeutic advances, and future directions.代谢、炎症和肿瘤疾病中的核受体：作用机制、治疗进展及未来方向
Eur J Med Res. 2025 Sep 9;30(1):843. doi: 10.1186/s40001-025-03073-6.
2
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.SOX2利用FOXA1作为异源转录伙伴来驱动去势抵抗性前列腺癌的增殖。
bioRxiv. 2025 Jul 19:2025.07.18.664790. doi: 10.1101/2025.07.18.664790.
3
Fractional order modeling of prostate cancer with pulsed treatment and the impact of effector cell killing and cell competition.

本文引用的文献

1
Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits.谱系可塑性使低内质网腔肿瘤能够进化并获得基底样特征。
Breast Cancer Res. 2023 Mar 1;25(1):23. doi: 10.1186/s13058-023-01621-8.
2
Aggressive pituitary tumors (PitNETs).侵袭性垂体肿瘤（垂体神经内分泌肿瘤）
Endocr J. 2023 Mar 28;70(3):241-248. doi: 10.1507/endocrj.EJ23-0007. Epub 2023 Mar 3.
3
Cancer statistics, 2023.癌症统计数据，2023 年。
前列腺癌脉冲治疗的分数阶建模以及效应细胞杀伤和细胞竞争的影响
Sci Rep. 2025 Apr 12;15(1):12580. doi: 10.1038/s41598-025-96737-6.
4
The Homeobox Transcription Factor NKX3.1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells.同源框转录因子NKX3.1在去势抵抗性前列腺癌细胞中发挥致癌作用。
Cancers (Basel). 2025 Jan 18;17(2):306. doi: 10.3390/cancers17020306.
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
4
Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells.非传统的异喹啉类选择性雌激素受体调节剂在雌激素受体阳性乳腺癌细胞中引发类似氟维司群的转录程序。
NPJ Breast Cancer. 2022 Dec 14;8(1):130. doi: 10.1038/s41523-022-00497-9.
5
ESR1 activating mutations: From structure to clinical application.ESR1激活突变：从结构到临床应用
Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188830. doi: 10.1016/j.bbcan.2022.188830. Epub 2022 Nov 4.
6
ZBTB20 Regulates Prolactin Expression and Lactotrope Function in Adult Mice.ZBTB20调节成年小鼠催乳素的表达和促乳素细胞功能。
Endocrinology. 2022 Oct 23;163(12). doi: 10.1210/endocr/bqac181.
7
SERDs: a case study in targeted protein degradation.选择性雌激素受体降解剂：靶向蛋白降解的案例研究。
Chem Soc Rev. 2022 Oct 3;51(19):8149-8159. doi: 10.1039/d2cs00117a.
8
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.DLL3 作为神经内分泌肿瘤治疗的新兴靶点。
Oncologist. 2022 Nov 3;27(11):940-951. doi: 10.1093/oncolo/oyac161.
9
Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance.转录共激活因子MED1在抗雌激素和抗HER2治疗耐药性的关联中发挥作用。
Cancer Drug Resist. 2022 Jun 1;5(2):498-510. doi: 10.20517/cdr.2022.33. eCollection 2022.
10
CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.CREB5 重编程 FOXA1 核相互作用以促进对雄激素受体靶向治疗的耐药性。
Elife. 2022 May 12;11:e73223. doi: 10.7554/eLife.73223.